Anand Patel

University of Chicago — United States

Medicine · Health Sciences

21h-index1.6kcitations311works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(103), Acute Lymphoblastic Leukemia research(78), Chronic Myeloid Leukemia Treatments(66), Myeloproliferative Neoplasms: Diagnosis and Treatment(51), Chronic Lymphocytic Leukemia Research(25)

Publications311 total

Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors
Haematologica·2026Open Access
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia
Haematologica·2026Open Access
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.
Blood Advances·2026· 1 citedOpen Access
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms
Blood Advances·2026Open Access
Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the ‘unclassifiable’
Current Opinion in Hematology·2025
Characterization of chromosome 5 aberrations in <i>TP53</i> mutated myeloid neoplasms with ≥5% blasts: An International <i>TP53</i> Investigators Network (iTiN) study
Cancer·2025Open Access
CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study
Value in Health·2025
Supplementary Table 1 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
2025Open Access
Supplementary figures 1-9 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
2025Open Access
Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study
Blood·2025Open Access
Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
Blood·2025Open Access
Abstract 4372348: Characterization and Prognostic Implications of Pulmonary Hypertension on Right Heart Catheterization Among Patients with Myeloproliferative Neoplasms
Circulation·2025
County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado
Blood·2025Open Access
Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes
Blood·2025Open Access
Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study
Blood·2025Open Access
Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms
Blood·2025Open Access
The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis
Blood·2025Open Access
A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia
Blood·2025Open Access
Hairy cell leukemia treatment strategies: A real-world multicenter experience
Blood·2025Open Access
Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms
Blood·2025Open Access
page 1 of 16Next →

Frequent Co-authors

Olatoyosi Odenike(12), Talha Badar(11), Wendy Stock(9), Rory M. Shallis(9), Mark R. Litzow(9), Madelyn Burkart(8), Ehab Atallah(7), Adam DuVall(7), Yasmin Abaza(7), Guru Subramanian Guru Murthy(7), Shira Dinner(6), Antoine N. Saliba(5), Jan Philipp Bewersdorf(5), James M. Foran(5), Mehrdad Hefazi(5), Sandeep Gurbuxani(5), Richard A. Larson(5), Caner Saygin(5), Irum Khan(4), Neil Palmisiano(4)